Mushroom-derived polysaccharides in cancer immunotherapy: mechanisms, human evidence, and translational priorities.

Authors

Sylvester Chibueze Izah, Ebinyo Rebecca Aseibai, Kingsley Excel Dunga, Matthew Chidozie Ogwu, Vivian Ibienebakabobo Promise, Nsikak Godwin Etim, Irene Nneka Ohanusi

Published in

Frontiers in oncology. Volume 16. Pages 1955408. Epub Sep 30, 2026.

Abstract

Mushroom-derived polysaccharides are widely promoted as anticancer immune modulators, but interpretation is weakened by imprecise product identity, chemically non-equivalent preparations, and extrapolation across evidence levels. This critical narrative review evaluates beta-glucans, heteropolysaccharides, polysaccharide-protein complexes, crude fractions, modified derivatives, and multicomponent extracts as preparation-specific adjunct candidates. Receptor-level evidence is strongest for general fungal beta-glucan systems, particularly Dectin-1/Syk/CARD9 signaling and conditional complement receptor 3 cooperation; direct transfer of those mechanisms to individual mushroom preparations requires product-specific causal testing. Selected animal studies support myeloid remodeling, dendritic-cell and natural-killer-cell effects, and T-cell activation, but route, exposure, product characterization, and model limitations constrain translation. Human evidence remains heterogeneous: historical randomized PSK studies reported benefit in specific adjuvant chemotherapy settings, a later phase III lentinan trial was negative for overall survival, and small maitake, Agaricus, and pleuran studies mainly report immune surrogates. Direct clinical evidence with checkpoint inhibitors, therapeutic antibodies, or cancer vaccines is not established. The field should therefore move from species-level claims to product-level development with authenticated source material, orthogonal structural analysis, contaminant control, mechanism-linked potency, route-specific pharmacokinetics, tumor pharmacodynamics, and randomized testing against contemporary standard care. Mushroom-derived polysaccharide immunomodulators remain plausible research candidates, but neither the class nor unstandardized mushroom foods or supplements are clinically validated substitutes for established cancer treatment.

PMID:
42877591
Bibliographic data and abstract were imported from PubMed on 16 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.